logo
From compliance to confidence: Toward transparent and trusted food systems

From compliance to confidence: Toward transparent and trusted food systems

Every year on June 7, World Food Safety Day reminds us of a simple but critical truth: access to safe food is a shared responsibility and a public good. The theme for World Food Safety Day 2025 is "Food safety: science in action". This theme highlights the crucial role of scientific knowledge in ensuring food safety, from developing safe practices to addressing foodborne illnesses, according to the World Health Organization (WHO). With consumers growing more vocal about what goes into their food and increasing scrutiny of terms like 'flavour enhancers' and 'chemical preservatives', conversations around food safety have moved from niche policy circles to public discourse.
Against this backdrop, a recent Stakeholder Engagement Workshop on Food Additive Safety and Toxicity(SEW FAST), hosted by CSIR-IITR and the Food Future Foundation, took place in Lucknow. It brought together scientists, industry experts, and regulators to examine the persistent gulf between public perception and scientific evidence around food additives.
Food additives play a crucial role in preservation, taste enhancement, stability, and nutritional fortification of food. They are especially important in ensuring food safety and security in a country as vast and diverse as India. From ensuring shelf-life in variable hot and humid climates to supporting sodium-reduction strategies through flavour modulators, additives serve both technological and public health purposes. Still, public wariness around food additives remains. A clear example is monosodium glutamate (MSG), which has faced more scrutiny than most.
Recent scientific and regulatory evaluations conducted by authoritative bodies across the world, including Food Standards Australia New Zealand, European Commission, WHO, Food and Agriculture Organization (FAO), the US Food and Drug Administration (FDA) and even Food Safety and Standards Authority of India (FSSAI) have consistently affirmed its safety. Yet, legacy perceptions persist which feed certain warning labels. The time has now come to bring regulatory clarity to food additives such as MSG and re-establish public trust through evidence-based policymaking.
MSG is a naturally derived sodium salt of glutamic acid, an amino acid abundantly found in foods like tomatoes, mushrooms, cheese, and even human breast milk. It enhances flavor through the umami taste, helping make food more palatable, especially for vulnerable populations like the elderly. It has been misrepresented as harmful for far too long, and it is essential to address this gap between perception and scientific reality.
In India, food products containing MSG are still required to carry a warning label: 'Not Recommended for Infants and Pregnant Women.' While this requirement reflected the precautionary approach of its time, today's scientific landscape has evolved significantly. Comprehensive global reviews have reaffirmed the safety of MSG, including for sensitive populations, which is less than 1 per cent. As science progresses, policy must have the flexibility to evolve with it ,creating a balance between local relevance and global alignment, ensuring that regulations protect public health, support trade, and respect India's unique characteristics. Updating labelling practices in line with current evidence offers an opportunity not only to align with international standards, but also to strengthen consumer confidence and encourage innovation.
This matters for public health. For example, MSG has the potential to support sodium reduction strategies. MSG contains only about 12 per cent sodium, compared to 39 per cent in table salt. Replacing salt partially with MSG in recipes can reduce overall sodium content by up to 30 per cent without sacrificing taste, which is a benefit recognised by the US Institute of Medicine and numerous public health experts.
So, what can we do with this knowledge?
As consumer awareness grows and food systems become more complex, our regulatory frameworks must evolve. A few principles can guide this shift:
Existing models often assume worst-case scenarios of daily maximum consumption. Instead, the country needs an India--specific Food Additive Intake Model (FAIM), based on real dietary data, population groups (infants, elderly, pregnant women), and seasonal consumption. This would enable more realistic estimation of scenario on daily exposure as well as also less than life time, apart from chronic exposure, and may reduce excessive conservatism in identifying safety margin.
Regulatory decisions must be communicated to the consumer with clarity, especially the difference between hazard (potential harm) and risk (likelihood of harm) in simple terms. Establishing interdisciplinary advisory councils and platforms for consumer-scientist dialogue can help demystify policies and enhance public trust.
India's precautionary labeling laws, such as those on MSG, have not kept pace with recent development of science. As seen in the iron-fortified rice precedent, labels can be updated when evidence evolves. Doing so signals regulatory maturity and consumer respect. It's a collaborative and dynamic process, far from a mere legacy.
The theme of World Food Safety Day 2025 reminds us, in the subject of MSG, the crucial role of scientific knowledge in ensuring food safety, from developing safe practices.
Regulations must be proactive and forward-looking, not merely reactive. By embedding science into the policymaking process, and not just at the end, we can anticipate risks better and foster innovation responsibly. The goal is not to silence scrutiny, but to enable informed scrutiny.
As India prepares to take greater leadership in global food policy, let us ensure our food additive regulations are not just robust, but also scientifically rational. In the case of food additives, that means recognizing the overwhelming scientific consensus, removing unnecessary warnings, and allowing science, not stigma to guide the way.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NB.1.8.1 Covid-19 variant makes up 10% cases globally: Should you worry?
NB.1.8.1 Covid-19 variant makes up 10% cases globally: Should you worry?

Business Standard

time28 minutes ago

  • Business Standard

NB.1.8.1 Covid-19 variant makes up 10% cases globally: Should you worry?

Just when many believed Covid-19 was in the rear-view mirror, a new variant has quietly gained ground. NB.1.8.1, first detected in China in January 2025, now accounts for one in ten Covid-19 cases globally—up from just one in forty a month ago. It has spread across twenty-two countries so far. What is NB.1.8.1 variant? According to the World Health Organization, NB.1.8.1 is among several fast-evolving Omicron-lineage variants. From January to May 2025, global dominance shifted from XEC to LP.8.1, with NB.1.8.1 now surging rapidly. The WHO has classified NB.1.8.1 as a Variant Under Monitoring due to its rise in prevalence and potential public health implications. Officials stress that while vigilance is crucial, there is no cause for alarm. Vaccination remains the best protection against severe illness and death. How NB.1.8.1 behaves and how severe it really is NB.1.8.1 is a sublineage of the Omicron JN.1 family. It carries similar characteristics—high transmissibility, but mostly mild to moderate illness. It also includes new mutations on the spike protein, which may enhance its ability to spread and evade immunity. So far, there is no evidence to suggest NB.1.8.1 causes more severe disease, hospitalisations or death compared to previous variants. NB.1.8.1 symptoms: What to watch for Common symptoms include: Dry, persistent cough Runny or blocked nose Fatigue and general body aches Sore throat Fever or chills Headache or hoarseness in some cases Many report being able to go about daily activities but feel unusually tired and sluggish. Are vaccines still effective against NB.1.8.1? Updated vaccines, including the latest Omicron-targeted boosters, are designed to protect against the JN.1 family. While they may not prevent all infections, they continue to reduce the risk of hospitalisation and severe outcomes. Expert guidance includes: If you are over sixty, have chronic health conditions or are immunocompromised, get a booster if it has been more than six months since your last dose If you are healthy and under sixty, no new dose is required at present Use masks in public transport and crowded indoor spaces How to manage NB.1.8.1 symptoms at home In most cases, NB.1.8.1 does not require hospitalisation. Here is what helps: Rest and stay well hydrated Use paracetamol or other over-the-counter medications for fever or aches Recovery generally takes five to seven days If you are elderly or immunocompromised, speak to your doctor early. Antiviral medication is most effective within five days of the onset of symptoms. Warning signs: When to seek emergency help Seek urgent medical care if you experience any of the following: Difficulty breathing Chest pain or tightness Confusion or trouble staying awake Severe dizziness or fainting Do not panic, but stay informed Experts believe NB.1.8.1 will follow a familiar seasonal pattern seen with earlier variants—periodic surges during winter and summer months. Most infections remain mild. Vaccines continue to work. Keep an eye on symptoms, isolate if unwell, and consult your doctor when in doubt.

Consumer Choice Center Advocates for Significant Revisions to WHO Governance and Operations Amidst Approval of Increased Mandatory Membership
Consumer Choice Center Advocates for Significant Revisions to WHO Governance and Operations Amidst Approval of Increased Mandatory Membership

Hans India

timean hour ago

  • Hans India

Consumer Choice Center Advocates for Significant Revisions to WHO Governance and Operations Amidst Approval of Increased Mandatory Membership

India: The World Health Organization (WHO) is facing intense scrutiny following the approval of a 20% increase in mandatory membership dues, amounting to an additional $120 million per year extracted directly from taxpayers Consumer Choice Center joins critics in questioning whether the organization truly deserves this financial boost, citing significant issues with transparency, accountability, and the allocation of funds. In a country like India, where over 60% of health expenditure is out-of-pocket and public health systems remain severely underfunded, questions around the WHO's spending priorities resonate deeply. The World Health Organization (WHO) recently announced an increase in its mandatory membership dues-known as assessed contributions—by 20%. For 2026 and 2027, this will amount to an additional $120 million per year , drawn straight from taxpayers around the globe. The WHO allocates funding through both voluntary contributions, which are earmarked for specific health programs, and assessed contributions. Assessed contributions provide the WHO leadership, including Director-General Tedros Adhanom Ghebreyesus, with greater discretion in how the funds are utilized. These funds are directed into flexible funding streams. This occurs while global healthcare systems experience challenges related to underfunding, growing waitlists, and staff shortages. Funds are being allocated to various initiatives, including upgrades to the WHO's Geneva headquarters. Senior staff benefits include education allowances of $33,000 per child. The total annual cost for the WHO's 301 most senior staff is approximately $130 million, averaging $432,000 per person, inclusive of benefits and allowances. Sharing his thoughts on the potential utilisation of these additional funds, Fred Roeder, Managing Director, Consumer Choice Center said, 'The $120 million being extracted in new dues each year could directly fund healthcare for 15,000 Germans, 40,000 Poles, 82,000 Georgians, 100,000 South Africans and 500,000 Indians . In India, $120 million annually could fund cancer treatment for 40,000 patients under Ayushman Bharat or cover the full immunization of over 2 million children. That same amount could also strengthen tobacco cessation services across the country, which remain vastly under-resourced despite India having over 260 million tobacco users . Even more troubling, this shift toward 'core funding' is part of a deliberate WHO strategy: to move away from specific, donor-driven initiatives and toward general budget increases it can spend at will—on salaries, travel, and yes, real estate. These are not funds being poured into pandemic preparedness or child vaccination programs. They are being funnelled into a top-heavy administrative structure with minimal transparency and questionable accountability.' The WHO's defenders argue that the organization needs more freedom to respond to global health threats. But freedom without scrutiny leads to mission drift and misallocation. The organization already has a poor record of pandemic response and a reputation for political entanglements. Its handling of tobacco control in India reflects this too—offering ideological prescriptions rather than collaborative, evidence-based support that balances public health, trade, and economic development. The last thing it needs is a blank check. The world needs a lean, targeted health response team. Let's refocus the WHO on solving global health crises, prioritizing impact over institutional expansion. National governments should refuse further increases to assessed contributions until the WHO commits to radical transparency reforms, trims senior compensation packages, and rededicates itself to programmatic funding that puts patient care first. We owe that much to the people who are actually sick—and not just those with corner offices in Geneva. India, as a G20 leader and a major player in global health diplomacy, should demand accountability before committing more taxpayer funds. It must condition future WHO funding on results-driven support for local challenges—like modernizing tobacco regulation, enabling farmer transitions, and enforcing traceability to combat the illicit trade that harms both public health and revenue. Consumer Choice Center The Consumer Choice Center is an independent, non-partisan consumer advocacy group championing the benefits of freedom of choice, innovation, and abundance in everyday life. Through research and educational outreach, we advocate for smart policies that promote growth, lifestyle choice, and tech innovation. We empower consumers to raise their voice and fight for their right to choose—whether it's the products they buy, the technologies they use, or the lifestyle they live.

We can forget COVID-19, it's not a cause for concern, say health experts, as they explain the reason behind the surge in India
We can forget COVID-19, it's not a cause for concern, say health experts, as they explain the reason behind the surge in India

Time of India

timean hour ago

  • Time of India

We can forget COVID-19, it's not a cause for concern, say health experts, as they explain the reason behind the surge in India

COVID-19 is becoming milder, but occasional surges are expected. Experts say the virus is endemic and constantly evolving. Rising cases are due to waning immunity and seasonal factors. Vulnerable populations should take precautions. The WHO declared the end of COVID-19 as a public health emergency two years ago. Cases are rising in Southeast Asia, including India. Tired of too many ads? Remove Ads Covid Becoming Milder Every Passing Year: Expert Tired of too many ads? Remove Ads Surge in India part of broader trend Tired of too many ads? Remove Ads 'Ups and downs expected because the virus is endemic' COVID-19 is becoming less severe over time, but occasional increases in cases are expected as the virus becomes endemic and continues to change, scientists say. They reassure the public that there is no major cause for alarm. The experts addressed concerns about the rising number of cases in different parts of India . They believe it is due to weakening immunity combined with seasonal factors, such as extreme temperatures that cause people to stay indoors in air-conditioned environments. They emphasised the need for caution, especially for those who are more vulnerable."With every passing year, COVID-19 is causing milder infections. It is (now) just another respiratory illness and less dangerous than flu. We can forget COVID-19 as a special case. It is not a cause of concern," said Dr. Chandrakant Lahariya, a global health Agarwal from Ashoka University added, "All the subvariants are similar, having a lower virulence but high infectivity. While highly susceptible people can still get severe disease, the vast majority don't, especially those who have had prior infections or vaccines."The World Health Organization (WHO) declared the end of COVID-19 as a public health emergency in May 2023. Health experts now describe the disease as seasonal, endemic, or restricted to certain of June 6, there were over 5,300 active cases in India, with nearly 500 new cases reported in the last 24 hours. More than 4,700 people have recovered. Since January, 55 deaths have been reported, mainly among individuals with pre-existing conditions, according to the Union Health advised that "People with pre-existing illnesses and those older than 65 should follow standard precautions, as they would against any other respiratory infection -- not just for COVID-19."Kerala is the most affected state with over 1,600 cases, followed by Gujarat, West Bengal, Delhi, and Maharashtra, according to ministry increase in cases in India is part of a broader trend in Southeast Asia, including Singapore, Malaysia, Thailand, and Hong surveillance by the Council of Scientific and Industrial Research-National Chemical Laboratory (NCL) has detected the presence of the virus in samples from sewage treatment plants in Pune, according to the Times of sequencing of samples from western and southern India has shown links to Omicron subvariants LF.7, XFG, JN.1, and NB.1.8.1. Rajiv Behl, Director General of the Indian Council of Medical Research (ICMR), said earlier this week that the cases are not severe and there is no need to WHO has classified LF.7 and NB.1.8.1 as 'variants under monitoring' (VUM). JN.1 has been circulating in India since November Satyajit Rath explained that the subvariants are likely better at binding to human cells, despite existing antibodies."However, the important issue here is not their infectivity, but their tendency to cause severe disease, or 'virulence'," Rath experts said that ups and downs in infections are expected because the virus is now endemic and constantly stated, "People need not worry themselves until they are informed of a new 'variant of concern'. VUM is not relevant to the public, but only to public health authorities."Lahariya advised the public to get information from reliable sources and avoid sharing unverified messages. Rath suggested monitoring the virulence of new emphasised that "National and state governments in India should keep a watch on cases, monitor the trends in new cases and share data widely. The linkage between infections and clinical outcomes should be explored to understand the clinical features of the variants in circulation."Rath highlighted the need to address systemic issues in public health systems and healthcare questioned, "Are we making next-generation Covid vaccines at all? Are we making them available widely and affordably? Are we even carefully tracking evidence to see how well or poorly the current vaccine-induced immunity functions against emerging strains?"He added, "And if not, we are throwing poor communities onto their own resources even for taking such simple precautions, and that is a systemic problem."(Inputs from PTI)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store